Related Experiment Video
Updated: Oct 11, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.9K
Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma
Corrado Pelaia1, Claudia Crimi2, Nunzio Crimi2
1Department of Health Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy.
Expert Review of Respiratory Medicine
|November 30, 2021
Summary
New triple-therapy inhalers combining long-acting beta-agonists, inhaled corticosteroids, and long-acting muscarinic antagonists offer improved asthma control. This fixed-dose combination therapy enhances lung function and patient adherence for uncontrolled asthma.
Area of Science:
- Respiratory Medicine
- Pharmacology
- Clinical Trials
Background:
- Asthma management often requires combination therapy.
- Long-acting beta-agonist/inhaled corticosteroid (LABA/ICS) may be insufficient for uncontrolled asthma.
- Long-acting muscarinic antagonist (LAMA) is recommended as add-on therapy.
Purpose of the Study:
- To review clinical studies on fixed-dose LABA/LAMA/ICS combinations.
- To evaluate the efficacy and safety of indacaterol/glycopyrronium/mometasone (IND/GLY/MF).
Main Methods:
- PubMed database search for recent clinical studies.
- Review of safety and efficacy data for LABA/LAMA/ICS combinations.
Main Results:
- IND/GLY/MF is the first single-inhaler, fixed-dose triple therapy approved in Europe.
- IND/GLY/MF demonstrated superiority over LABA/ICS in improving lung function.
- Digital companion integration improved adherence and reduced rescue inhaler use.
Conclusions:
- IND/GLY/MF offers a novel approach for uncontrolled asthma.
- Triple therapy improves lung function, adherence, and patient satisfaction.
- This combination therapy represents a significant advancement in asthma treatment.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
443
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
443
01:23Inhaled Medications
469
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
469
01:30Asthma-IV: Diagnostic and Management
2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
675
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
675
01:24Antiasthma Drugs: Methylxanthines
592
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
592
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
654
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
654